Neoplasms
|
group |
Neoplasms
|
Neoplastic Process
|
10161
|
1644
|
0.100 |
None |
1.000 |
10 |
|
2001 |
2019 |
Mammary Neoplasms
|
group |
Neoplasms; Skin and Connective Tissue Diseases
|
Neoplastic Process
|
2780
|
385
|
0.330 |
None |
1.000 |
4 |
|
2005 |
2018 |
Malignant Neoplasms
|
group |
Neoplasms
|
Neoplastic Process
|
8621
|
1641
|
0.030 |
None |
1.000 |
3 |
|
2013 |
2016 |
Primary malignant neoplasm
|
group |
Neoplasms
|
Neoplastic Process
|
8221
|
1374
|
0.030 |
None |
1.000 |
3 |
|
2013 |
2016 |
Anxiety Disorders
|
group |
Mental Disorders
|
Mental or Behavioral Dysfunction
|
840
|
163
|
0.200 |
None |
1.000 |
1 |
|
2010 |
2010 |
Colorectal Neoplasms
|
group |
Digestive System Diseases; Neoplasms
|
Neoplastic Process
|
1296
|
609
|
0.010 |
None |
1.000 |
1 |
|
2007 |
2007 |
Liver neoplasms
|
group |
Digestive System Diseases; Neoplasms
|
Neoplastic Process
|
1424
|
7
|
0.300 |
None |
1.000 |
1 |
|
2016 |
2016 |
Lung Neoplasms
|
group |
Neoplasms; Respiratory Tract Diseases
|
Neoplastic Process
|
1486
|
39
|
0.010 |
None |
1.000 |
1 |
|
2018 |
2018 |
Metabolic Diseases
|
group |
Nutritional and Metabolic Diseases
|
Disease or Syndrome
|
945
|
50
|
0.010 |
None |
1.000 |
1 |
|
2018 |
2018 |
Prostatic Neoplasms
|
group |
Neoplasms; Male Urogenital Diseases
|
Neoplastic Process
|
1722
|
31
|
0.300 |
None |
1.000 |
1 |
|
2018 |
2018 |
Uterine Fibroids
|
group |
Neoplasms
|
Neoplastic Process
|
569
|
154
|
0.010 |
None |
1.000 |
1 |
|
2009 |
2009 |
B-Cell Lymphomas
|
group |
Neoplasms; Immune System Diseases; Hemic and Lymphatic Diseases
|
Neoplastic Process
|
1408
|
42
|
0.010 |
None |
1.000 |
1 |
|
2018 |
2018 |
Disorder of endocrine ovary
|
group |
Female Urogenital Diseases and Pregnancy Complications; Endocrine System Diseases
|
Disease or Syndrome
|
22
|
1
|
0.010 |
None |
1.000 |
1 |
|
2012 |
2012 |
Gastrointestinal Stromal Tumors
|
group |
Digestive System Diseases; Neoplasms
|
Neoplastic Process
|
538
|
154
|
0.010 |
None |
1.000 |
1 |
|
2016 |
2016 |
Hematologic Neoplasms
|
group |
Neoplasms; Hemic and Lymphatic Diseases
|
Neoplastic Process
|
827
|
60
|
0.010 |
None |
1.000 |
1 |
|
2003 |
2003 |
Pervasive Development Disorder
|
group |
Mental Disorders
|
Mental or Behavioral Dysfunction
|
328
|
49
|
0.010 |
None |
1.000 |
1 |
|
2018 |
2018 |
Secondary Neoplasm
|
group |
Pathological Conditions, Signs and Symptoms; Neoplasms
|
Neoplastic Process
|
2492
|
85
|
0.010 |
None |
1.000 |
1 |
|
2016 |
2016 |
Forced expiratory volume function
|
phenotype |
|
Organ or Tissue Function
|
272
|
1169
|
0.100 |
None |
1.000 |
2 |
2
|
2015 |
2019 |
Body mass index
|
phenotype |
|
Clinical Attribute
|
1014
|
2689
|
0.100 |
None |
1.000 |
2 |
1
|
2019 |
2019 |
Acute-Phase Reaction
|
phenotype |
Pathological Conditions, Signs and Symptoms
|
Pathologic Function
|
24
|
|
0.200 |
None |
1.000 |
1 |
|
2010 |
2010 |
Neoplasm Metastasis
|
phenotype |
Pathological Conditions, Signs and Symptoms; Neoplasms
|
Neoplastic Process
|
6385
|
327
|
0.010 |
None |
1.000 |
1 |
|
2016 |
2016 |
Vital capacity
|
phenotype |
|
Clinical Attribute
|
430
|
746
|
0.100 |
None |
1.000 |
1 |
1
|
2019 |
2019 |
Tumor Progression
|
phenotype |
Pathological Conditions, Signs and Symptoms
|
Neoplastic Process
|
3865
|
72
|
0.010 |
None |
1.000 |
1 |
|
2016 |
2016 |
C-reactive protein measurement
|
phenotype |
|
Laboratory Procedure
|
135
|
624
|
0.100 |
None |
1.000 |
1 |
1
|
2018 |
2018 |
Low density lipoprotein cholesterol measurement
|
phenotype |
|
Laboratory Procedure
|
483
|
1142
|
0.100 |
None |
1.000 |
1 |
1
|
2012 |
2012 |